Hidradenitis Suppurativa (HS) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Hidradenitis Suppurativa (HS) Emerging Therapy and TPP Insights

Thelansis's "Hidradenitis Suppurativa (HS) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Hidradenitis Suppurativa (HS) Overview

Hidradenitis suppurativa is a chronic, systemic inflammatory follicular disorder characterized by recurrent, painful deep-seated nodules, abscesses, draining sinus tracts, and progressive scarring. Although lesions manifest anatomically in intertriginous zones rich in apocrine glands, the primary pathobiology is rooted in hyperkeratosis and occlusion of the terminal hair follicle infundibulum followed by follicular rupture, immune dysregulation, and secondary microbial propagation. Diagnosis is clinical, utilizing the Hurley staging system to direct intervention and tracking metabolic comorbidities. Management in 2026 transitions rapidly from acute lifestyle and empiric antibiotic suppression to target-specific biological therapies for moderate-to-severe disease. While TNF-alpha inhibition remains foundational, molecular strategies widely utilize advanced interleukin-17A and interleukin-17A/F inhibitors to achieve sustained skin clearance and reduce inflammatory tunnel formation, complemented by wide surgical excision or deroofing procedures for anatomically fixed fibrotic disease structures.

Key Highlights

• In France, diagnosed Hidradenitis Suppurativa (HS) cases are projected to increase from 138,486 in 2025 to 178,286 by 2035.
• HS is a chronic, recurrent inflammatory skin disease associated with painful lesions, abscess formation, and progressive scarring.
• The disease imposes a substantial physical and psychosocial burden, significantly affecting patients' quality of life.
• Delayed diagnosis and limited long-term treatment options continue to contribute to persistent disease activity and unmet patient needs.

Market Overview

• The France HS market is projected to grow from $205M in 2025 to $620M by 2035.
• Market growth is driven by:
• Increasing adoption of biologic therapies targeting key inflammatory pathways
• Growing disease awareness and improved diagnosis of moderate-to-severe HS cases
• Future growth will depend on the successful development of novel targeted therapies capable of achieving sustained disease control and improving long-term patient outcomes.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Avalo Therapeutics, Inc.
• ACELYRIN Inc.
• Incyte Corporation
• Novartis Pharmaceuticals
• UCB Biopharma SRL
• Aclaris Therapeutics, Inc.
• Takeda
• Sanofi
• Merck Sharp & Dohme LLC
• Sonoma Biotherapeutics, Inc.
• Almirall, S.A.
• Shanghai Huaota Biopharmaceutical Co., Ltd.
• Eli Lilly and Company
• AbbVie
• Insmed Incorporated
• Pfizer
• Boehringer Ingelheim
• MoonLake Immunotherapeutics AG
• Vanda Pharmaceuticals
• Janssen Research & Development, LLC
• Bluefin Biomedicine, Inc.
• Navigator Medicines, Inc.
• Sinocelltech Ltd.
• Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
• Zura Bio Inc.